1158results about How to "Inhibit binding" patented technology

Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and / or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by simultaneously inhibiting the PD-1 ligands, PD-L1 and PD-L2. The immune response can be modulated by providing antagonists which bind with different affinity, by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again. In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation.

The disclosure provides compositions and methods relating to or derived from anti-activin A binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin A antibodies that bind human activin A, activin A-binding fragments and derivatives of such antibodies, and activin A-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having activin A-related disorders or conditions including cachexia related to gonadal cancer, other cancers, rheumatoid arthritis, and other diseases.

Methods, compositions and arrays for non-random loading of single analyte molecules into array structures are provided.

Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.

Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions and methods using the new VEGF-specific antibodies are also provided.

This document describes an optical sensor unit and a procedure for the specific detection and identification of biomolecules at high sensitivity in real fluids and tissue homogenates. High detection limits are reached by the combination of i) label-free integrated optical detection of molecular interactions, ii) the use of specific bioconstituents for sensitive detection and iii) planar optical transducer surfaces appropriately engineered for suppression of non-specific binding, internal referencing and calibration. Applications include the detection of prion proteins and identification of those biomolecules which non-covalently interact with surface immobilized prion proteins and are intrinsically involved in the cause of prion related disease.

The present invention features novel compositions, linkers, derivatized solid supports, and methods for the efficient solid phase synthesis of oligonucleotides, including RNA, DNA, RNA-DNA chimeras, and analogs thereof.

A system for removing an obstruction from a blood vessel includes an obstruction engaging element and an expandable capture element. The capture element preferably has a flexible cover and an expandable support structure. The engaging element engages the obstruction and moves the obstruction into the capture element. The capture element protects the obstruction when the obstruction is moved into the catheter.

The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

An anaerobic digester system has a vertically upright vessel, a matrix arranged in the vessel supporting a microorganism biomass thereon, an input for supplying an input slurry of liquid and suspended solids at an upper portion of the vessel above the matrix, a gas output at the top of the vessel for withdrawing gas generated by anaerobic digestion of solids, and an effluent output at the bottom of the vessel for withdrawing liquid and remaining solids. The vessel has a preferred liquid height to diameter ratio of 2 to 1, and is constructed of inert fiberglass-reinforced plastic coated with a translucent blue gel pigment layer for filtering light at wavelengths that promote biomass cultivation. The matrix is formed as an array of panels mounted to a spindle with wheels fixed at spaced intervals along its vertical height, and the panel are made of a polyethylene grass matting providing a high surface area to volume ratio of at least 20 to 1. Gas from the top of the vessel is recycled to the bottom to generate bubbles for mixing the feedstock. The related method of anaerobic digestion includes comminuting input wastes with a slurry grinder into a pumpable slurry 8-10 % by weight solids, and providing as the biomass hydrolytic bacteria, and fermentative bacteria including acetogenic and methanogenic bacteria to produce a methane gas product. Other products include an organic soil additive, bacterial solids plant food, and a filtrate used as plant tonic.

Disclosed is an expandable transluminal sheath, for introduction into the body while in a first, low cross-sectional area configuration, and subsequent expansion of at least a part of the distal end of the sheath to a second, enlarged cross-sectional configuration. The sheath is configured for use in the vascular system and has utility in the introduction and removal of balloon counterpulsation catheters. The access route is through the femoral arteries and the iliac arteries into the aorta, where an intra-aortic balloon pump catheter is positioned to provide cardiac support. The distal end of the sheath is maintained in the first, low cross-sectional configuration during advancement to the arteries into the aorta. The distal end of the sheath is subsequently expanded using a radial dilatation device.

A novel class of compounds, known as peptide nucleic acids, form double-stranded structures with one another and with ssDNA. The peptide nucleic acids generally comprise ligands such as naturally occurring DNA bases attached to a peptide backbone through a suitable linker.

Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-α and was developed to treat TNF-α mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.

Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula I

Described herein are methods and compositions for treating certain retinol-related diseases and conditions by modulation of transthyretin (TTR) and retinol binding protein (RBP) availability in the subject. For example, the methods and compositions provide for therapeutic agents for the treatment and / or prevention of age-related macular degeneration and / or dystrophies, metabolic disorders, idiopathic intracranial hypertension, hyperostosis, and protein misfolding and aggregation diseases. The compositions disclosed may be used as single agent therapy or in combination with other agents or therapies. In addition, described herein are methods and assays for selecting appropriate agents that can modulate the TTR and RBP availability in a subject.

A condenser coil for a refrigerated beverage and food service merchandiser includes a plurality of parallel fins be-tween adjacent tubes. In order to reduce the likelihood of fouling by the bridging of fibers therebetween, the spacing of the fins is maintained at a distance of 0.4 to 0.8 inches apart. In one embodiment, the tubes comprise microchannel tubes, with no fins there-between, and the spacing between the microchannel tubes is maintained in the range of 0.75 inches to optimize the heat transfer performance while minimizing the occurrence of fouling. A supporting structure is provided between microchannel tubes when no fins are included. Also, plural rows of microchannel tubes are provided with separate inlet headings and with the rows being stag-gered in transverse relationship to enhance the heat transfer characteristic while minimizing the likelihood of fouling.

The present invention discloses an adjustable forehead support for a nasal or full-face mask wherein the forehead support may be adjusted for the different shapes and sizes of a facial profile. The forehead support utilizes a dual-arm system that adjusts the position of the forehead support vis-á-vis the mask and / or airflow tube. The angle of the mask to the face may be adjusted with the present invention.

A forceps includes an end effector assembly having first and second jaw members. Each jaw member includes a proximal flange having an inwardly-facing surface. The proximal flanges are coupled to one another for moving the jaw members relative to one another between a first position and a second position for grasping tissue therebetween. The inwardly-facing surfaces of the proximal flanges are disposed in abutting relation relative to one another. A knife is configured to move along a knife path defined along an outwardly-facing surface of one of the proximal flanges. The knife is movable between a retracted position and an extended position, wherein the knife extends between the jaw members to cut tissue grasped therebetween.

Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.

Disclosed is a double stack box magazine for rimmed ammunition cartridges of varied lengths. It includes a housing having a neck portion in which cartridges are arranged in a single column, a double-stack portion in which cartridges are arranged in laterally alternating columns, and a transition portion between the neck portion and the double-stack portion. A pair of rim clearance channels is provided, on opposed interior lateral surfaces of the housing. A first channel portion allows clearance for cartridge rims without respect to forward and rearward position of the cartridges within the housing, which may vary depending on individual cartridge length. A second channel portion in the neck provides an abutment against which laterally opposed areas of a cartridge rim bear to shift the cartridge to a rearward position. A third channel portion provides transition between the first and second channel portions.

Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

This invention relates to a composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals comprising a probiotic Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve or Bifidobacterium longum and a fucosylated oligosaccharide selected from the group comprising 2′-fucosyllactose, 3′fucosyllactose, difucosyllactose, lacto-N-fucopentaose, lacto-N-fucohexaose, fucosyllacto-N-hexaose and fucosyllacto-N-neohexaose. The invention further extends to the use of such a composition in the prevention of opportunistic infections in immune-compromised individuals.